Background: Blood-based biomarkers have been proposed as an alternative to current sputum-based treatment monitoring methods in active tuberculosis (ATB). The aim of this study was to validate previously described phenotypic, activation, and cytokine markers of treatment response in a West African cohort. Methods: Whole blood immune responses to Mycobacterium tuberculosis ESAT-6/CFP-10 (EC) and purified protein derivative (PPD) were measured in twenty adults at baseline and after 2 months of standard TB treatment. Patients were classified as fast or slow responders based on a negative or positive sputum culture result at 2 months, respectively. Cellular expression of activation markers (CD38, HLA-DR), memory markers (CD27), and functional intracellular cytokine and proliferation (IFN-γ, Ki-67, TNF-α) markers were measured using multi-color flow cytometry. Results: There was a significant increase in the proportion of CD4+CD27+ cells expressing CD38 and HLA-DR following EC stimulation at 2 months compared to baseline (p = 0.0328 and p = 0.0400, respectively). Following PPD stimulation, slow treatment responders had a significantly higher proportion of CD8+CD27-IFN-γ+ (p = 0.0105) and CD4+CD27+HLA-DR+CD38+ (p = 0.0077) T cells than fast responders at baseline. Receiver operating curve analysis of these subsets resulted in 80% sensitivity and 70 and 100% specificity, respectively (AUC of 0.82, p = 0.0156 and 0.84, p = 0.0102). Conclusion: Our pilot data show reductions in expression of T cell activation markers were seen with treatment, but this was not associated with fast or slow sputum conversion at 2 months. However, baseline proportions of activated T cell subsets are potentially predictive of the subsequent speed of response to treatment.
Background: Blood-based biomarkers have been proposed as an alternative to current sputum-based treatment monitoring methods in active tuberculosis (ATB). The aim of this study was to validate previously described phenotypic, activation, and cytokine markers of treatment response in a West African cohort. Methods: Whole blood immune responses to Mycobacterium tuberculosis ESAT-6/CFP-10 (EC) and purified protein derivative (PPD) were measured in twenty adults at baseline and after 2 months of standard TB treatment. Patients were classified as fast or slow responders based on a negative or positive sputum culture result at 2 months, respectively. Cellular expression of activation markers (CD38, HLA-DR), memory markers (CD27), and functional intracellular cytokine and proliferation (IFN-γ, Ki-67, TNF-α) markers were measured using multi-color flow cytometry. Results: There was a significant increase in the proportion of CD4+CD27+ cells expressing CD38 and HLA-DR following EC stimulation at 2 months compared to baseline (p = 0.0328 and p = 0.0400, respectively). Following PPD stimulation, slow treatment responders had a significantly higher proportion of CD8+CD27-IFN-γ+ (p = 0.0105) and CD4+CD27+HLA-DR+CD38+ (p = 0.0077) T cells than fast responders at baseline. Receiver operating curve analysis of these subsets resulted in 80% sensitivity and 70 and 100% specificity, respectively (AUC of 0.82, p = 0.0156 and 0.84, p = 0.0102). Conclusion: Our pilot data show reductions in expression of T cell activation markers were seen with treatment, but this was not associated with fast or slow sputum conversion at 2 months. However, baseline proportions of activated T cell subsets are potentially predictive of the subsequent speed of response to treatment.
Authors: Toidi Adekambi; Chris C Ibegbu; Stephanie Cagle; Ameeta S Kalokhe; Yun F Wang; Yijuan Hu; Cheryl L Day; Susan M Ray; Jyothi Rengarajan Journal: J Clin Invest Date: 2015-03-30 Impact factor: 14.808
Authors: Katalin A Wilkinson; Tolu Oni; Hannah P Gideon; Rene Goliath; Robert J Wilkinson; Catherine Riou Journal: Am J Respir Crit Care Med Date: 2016-06-01 Impact factor: 21.405
Authors: Damien Portevin; Felicien Moukambi; Petra Clowes; Asli Bauer; Mkunde Chachage; Nyanda E Ntinginya; Elirehema Mfinanga; Khadija Said; Frederick Haraka; Andrea Rachow; Elmar Saathoff; Maximilian Mpina; Levan Jugheli; Fred Lwilla; Ben J Marais; Michael Hoelscher; Claudia Daubenberger; Klaus Reither; Christof Geldmacher Journal: Lancet Infect Dis Date: 2014-08-31 Impact factor: 25.071
Authors: Mohamed I M Ahmed; Nyanda E Ntinginya; Gibson Kibiki; Bariki A Mtafya; Hadija Semvua; Stellah Mpagama; Charles Mtabho; Elmar Saathoff; Kathrin Held; Rebecca Loose; Inge Kroidl; Mkunde Chachage; Ulrich von Both; Antelmo Haule; Anna-Maria Mekota; Martin J Boeree; Stephen H Gillespie; Michael Hoelscher; Norbert Heinrich; Christof Geldmacher Journal: Front Immunol Date: 2018-09-28 Impact factor: 7.561
Authors: Mohamed I M Ahmed; Christian Ziegler; Kathrin Held; Ilja Dubinski; Julia Ley-Zaporozhan; Christof Geldmacher; Ulrich von Both Journal: Front Pediatr Date: 2019-02-11 Impact factor: 3.418
Authors: G B Sigal; M R Segal; A Mathew; L Jarlsberg; M Wang; S Barbero; N Small; K Haynesworth; J L Davis; M Weiner; W C Whitworth; J Jacobs; J Schorey; D M Lewinsohn; P Nahid Journal: EBioMedicine Date: 2017-10-24 Impact factor: 8.143
Authors: Riccardo Arrigucci; Karim Lakehal; Pooja Vir; Deborah Handler; Amy L Davidow; Rosa Herrera; Julia Dolores Estrada-Guzmán; Yuri Bushkin; Sanjay Tyagi; Alfred A Lardizabal; Maria Laura Gennaro Journal: Front Immunol Date: 2018-09-19 Impact factor: 7.561
Authors: Hellen Hiza; Jerry Hella; Ainhoa Arbués; Mohamed Sasamalo; Veronica Misana; Jacques Fellay; Sébastien Gagneux; Klaus Reither; Damien Portevin Journal: Front Med (Lausanne) Date: 2022-04-15